Literature DB >> 18275000

Pharmacogenomics and therapeutics of hemoglobinopathies.

George P Patrinos1, Frank G Grosveld.   

Abstract

Individual genetic constitution is an important cause of variations in the response and tolerance to drug treatment. Single nucleotide polymorphisms (SNPs) in genes located within as well as outside the human beta-globin cluster have recently been shown to be significantly associated with Hb F increase in relation to hydroxyurea (HU) treatment in hemoglobinopathies patients. This article provides an update and discusses future challenges on the application of pharmacogenetic testing and pharmacogenomics for hemoglobinopathies therapeutics in relation to the current pharmacological treatment modalities for those disorders.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18275000     DOI： 10.1080/03630260701680367

Source DB:  PubMed          Journal:  Hemoglobin        ISSN： 0363-0269            Impact factor:   0.849


  7 in total

1.  Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach.

Authors:  Belinda Giardine; Joseph Borg; Douglas R Higgs; Kenneth R Peterson; Sjaak Philipsen; Donna Maglott; Belinda K Singleton; David J Anstee; A Nazli Basak; Barnaby Clark; Flavia C Costa; Paula Faustino; Halyna Fedosyuk; Alex E Felice; Alain Francina; Renzo Galanello; Monica V E Gallivan; Marianthi Georgitsi; Richard J Gibbons; Piero C Giordano; Cornelis L Harteveld; James D Hoyer; Martin Jarvis; Philippe Joly; Emmanuel Kanavakis; Panagoula Kollia; Stephan Menzel; Webb Miller; Kamran Moradkhani; John Old; Adamantia Papachatzopoulou; Manoussos N Papadakis; Petros Papadopoulos; Sonja Pavlovic; Lucia Perseu; Milena Radmilovic; Cathy Riemer; Stefania Satta; Iris Schrijver; Maja Stojiljkovic; Swee Lay Thein; Jan Traeger-Synodinos; Ray Tully; Takahito Wada; John S Waye; Claudia Wiemann; Branka Zukic; David H K Chui; Henri Wajcman; Ross C Hardison; George P Patrinos
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

2.  Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.

Authors:  Yu-Chi Chou; Ruei-Lin Chen; Zheng-Sheng Lai; Jen-Shin Song; Yu-Sheng Chao; Che-Kun James Shen
Journal:  Mol Cell Biol       Date:  2015-05-18       Impact factor: 4.272

3.  Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.

Authors:  George P Patrinos; David H K Chui; Ross C Hardison; Martin H Steinberg
Journal:  Expert Rev Hematol       Date:  2021-09-08       Impact factor: 2.819

Review 4.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 5.  Pharmacogenomics of sickle cell disease: steps toward personalized medicine.

Authors:  Marium Husain; Amber D Hartman; Payal Desai
Journal:  Pharmgenomics Pers Med       Date:  2017-10-19

Review 6.  Genome-based therapeutic interventions for β-type hemoglobinopathies.

Authors:  Kariofyllis Karamperis; Maria T Tsoumpeli; Fotios Kounelis; Maria Koromina; Christina Mitropoulou; Catia Moutinho; George P Patrinos
Journal:  Hum Genomics       Date:  2021-06-05       Impact factor: 4.639

Review 7.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.